media – Page 600 – DrugDu- Global Leading Pharmaceutical & Medical Device Platform

Changes in diet may improve life expectancy in Parkinson’s patients

New research from the University of Aberdeen shows that weight loss in people with Parkinson's disease leads to decreased life expectancy, increased risk of dementia and more dependency on care.
- Source: medicalxpress
- 556
- November 27, 2017
Dementia Parkinson's Researches
European Commission Approves TREMFYA® (guselkumab) for the Treatment of Moderate to Severe Plaque Psoriasis in the European Union

Janssen-Cilag International NV announced that the European Commission (EC) has approved TREMFYA® (guselkumab) for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy. Guselkumab is the first biologic that selectively blocks interleukin (IL)-23, a key driver of the immune inflammatory response in psoriasis.
- Source: Prnewswire
- 460
- November 27, 2017
interleukin Market Views plaque psoriasis TREMFYA
Brief Report on Exports of Chinese Vaccines in the First Three Quarters of 2017

In the first three quarters of 2017, the export sales of Chinese vaccines were 47.12 million USD with a slight increase of 6% over the same period of 2016.
- Source: Ddu
- 1,525
- November 27, 2017
export Market Reports vaccine
MS hug–What you need to know

For people with multiple sclerosis, an MS hug can be an unwelcome and painful part of their condition.
- Source: medicalnewstoday
- 670
- November 27, 2017
MS hug Researches
China Food and Drug Administration Approves Gilead’s Sovaldi® (Sofosbuvir) for Treatment of Chronic Hepatitis C Virus Infection

Gilead Sciences, Inc. (NASDAQ: GILD) announced that the China Food and Drug Administration (CFDA) has approved Sovaldi® (sofosbuvir 400mg), a once-daily oral nucleotide analog polymerase inhibitor for the treatment of chronic hepatitis C virus (HCV) infection. Sovaldi was approved for the treatment of adults and adolescents (aged 12 to 18 years) infected with HCV genotype 1, 2, 3, 4, 5 or 6 as a component of a combination antiviral treatment regimen. Sovaldi is the first Gilead HCV medicine approved in China.
- Source: Gilead
- 779
- November 27, 2017
CFDA Gilead Sciences HCV New Approvals Sovaldi®
Roche’s Erivedge no longer funded by the NHS

Roche’s Erivedge will indeed no longer be funded on the National Health Service(NHS) as a treatment for skin cancer after cost regulators issued final guidance ruling that it is not cost effective.
- Source: news.open-medical
- 549
- November 27, 2017
BCC Company Insight Erivedge NHS Roche skin cancer
Are These Four Viruses Present in Breast Tissue before Breast Cancer? – Medical News Bulletin

A study examines the association between viruses and breast cancer by examining the presence of the four viruses in normal breast tissue and after cancer development.
- Source: medicalempires
- 534
- November 24, 2017
breast cancer Researches
New cell death mechanism revealed

New research reveals how a dysfunction in the brain's so-called self-digestion system leads to cell death in neurodegenerative disorders. The newly discovered mechanism may lead to new therapies for conditions such as Parkinson's and Alzheimer's disease.
- Source: drugdu
- 716
- November 24, 2017
autophagy Dementia Huntington’s Disease neurodegenerative Parkinson's
Investors place bet on Chinese drugmakers

Chinese biotech groups are on target to raise about $10bn this year from venture capital funding, initial public offerings and licensing deals with overseas pharma companies, in what is partly a bet that Chinese-developed drugs can compete globally.
- Source: ft
- 872
- November 24, 2017
China drug innovation pharmaceutical R&D
Allegoric Receives FDA Approval For Use of VRAYLAR™ (cariprazine) in the Maintenance Treatment of Schizophrenia

Allergan plc (NYSE: AGN) announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for VRAYLAR™ (cariprazine) for the maintenance treatment of adults with schizophrenia. VRAYLAR is also approved in the U.S. in adults for the acute treatment of schizophrenia and acute treatment of manic or mixed episodes of bipolar I disorder.
- Source: Allergan
- 475
- November 24, 2017
bipolar I disorder FDA schizophrenia VRAYLAR™

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.